Literature DB >> 25900641

Methadone use in a male with the FMRI premutation and FXTAS.

Zukhrofi Muzar1,2, Reymundo Lozano2,3, Andrea Schneider2,3, Patrick E Adams2,3, Sultana M H Faradz1, Flora Tassone2,4, Randi J Hagerman2,3.   

Abstract

The fragile X-associated tremor ataxia syndrome (FXTAS) is caused by the premutation in FMR1 gene. Recent reports of environmental toxins appear to worsen the progression of FXTAS. Here we present a case of male adult with FXTAS and a long history of methadone use. The patient shows a faster progression in both symptoms of disease and MRI changes compared to what is typically seen in FXTAS. There has been no research regarding the role of narcotics in onset, progression, and severity of FXTAS symptoms. However, research has shown that narcotics can have a negative impact on several neurodegenerative diseases, and we hypothesize that in this particular case, methadone may have contributed to a faster progression of FXTAS as well as exacerbating white matter disease through RNA toxicity seen in premutation carriers.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  FMR1 gene; FXTAS; methadone; narcotics; premutation; white matter

Mesh:

Substances:

Year:  2015        PMID: 25900641      PMCID: PMC4845901          DOI: 10.1002/ajmg.a.37030

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  59 in total

1.  Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity.

Authors:  J R Caplehorn
Journal:  Drug Alcohol Rev       Date:  1998-03

2.  Increased risk of death in community-dwelling older people with white matter hyperintensities on MRI.

Authors:  Kevin A Kerber; Gregory T Whitman; Devin L Brown; Robert W Baloh
Journal:  J Neurol Sci       Date:  2006-08-04       Impact factor: 3.181

3.  White matter hyperintensities are an independent predictor of physical decline in community-dwelling older people.

Authors:  Jacqueline J J Zheng; Kim Delbaere; Jacqueline C T Close; Perminder Sachdev; Wei Wen; Henry Brodaty; Stephen R Lord
Journal:  Gerontology       Date:  2012-05-16       Impact factor: 5.140

4.  Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS).

Authors:  Alyssa A Hamlin; Dina Sukharev; Luis Campos; Yi Mu; Flora Tassone; David Hessl; Danh V Nguyen; Danuta Loesch; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2012-04-23       Impact factor: 2.802

5.  Chronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncoprotein in rat brain.

Authors:  M A Boronat; M J García-Fuster; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

6.  Brain tissue volumes and small vessel disease in relation to the risk of mortality.

Authors:  M Arfan Ikram; Meike W Vernooij; Henri A Vrooman; Albert Hofman; Monique M B Breteler
Journal:  Neurobiol Aging       Date:  2007-09-04       Impact factor: 4.673

7.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

8.  Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study.

Authors:  Cary S Kogan; Jeremy Turk; Randi J Hagerman; Kim M Cornish
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

Review 9.  The fragile-X premutation: a maturing perspective.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Am J Hum Genet       Date:  2004-03-29       Impact factor: 11.025

10.  Methadone-induced toxic leukoencephalopathy: MR imaging and MR proton spectroscopy findings.

Authors:  R A Salgado; P G Jorens; I Baar; P Cras; G Hans; P M Parizel
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-05       Impact factor: 3.825

View more
  16 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 2.  General Anesthetic Use in Fragile X Spectrum Disorders.

Authors:  Andrew Ligsay; Marwa El-Deeb; Maria J Salcedo-Arellano; Nina Schloemerkemper; Jeremy S Grayson; Randi Hagerman
Journal:  J Neurosurg Anesthesiol       Date:  2019-07       Impact factor: 3.956

Review 3.  [Fragile X associated tremor/ataxia syndrome: its clinical presentation, pathology, and treatment].

Authors:  M J Salcedo-Arellano; R J Hagerman; V Martinez-Cerdeno
Journal:  Rev Neurol       Date:  2019-03-01       Impact factor: 0.870

4.  A Majority of FXTAS Cases Present with Intranuclear Inclusions Within Purkinje Cells.

Authors:  Jeanelle Ariza; Hailee Rogers; Angela Monterrubio; Adriana Reyes-Miranda; Paul J Hagerman; Verónica Martínez-Cerdeño
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

5.  Women who carry a fragile X premutation are biologically older than noncarriers as measured by telomere length.

Authors:  Igor Albizua; Benjamin L Rambo-Martin; Emily G Allen; Weiya He; Ashima S Amin; Stephanie L Sherman
Journal:  Am J Med Genet A       Date:  2017-09-21       Impact factor: 2.802

Review 6.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

7.  Fragile X-Associated Tremor/Ataxia Syndrome in a Man in His 30s.

Authors:  Verónica Martínez-Cerdeño; Mirna Lechpammer; Aisha Lott; Andrea Schneider; Randi Hagerman
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

8.  Phenobarbital use and neurological problems in FMR1 premutation carriers.

Authors:  Wilmar Saldarriaga; Pamela Lein; Laura Yuriko González Teshima; Carolina Isaza; Lina Rosa; Andrew Polyak; Randi Hagerman; Santhosh Girirajan; Marisol Silva; Flora Tassone
Journal:  Neurotoxicology       Date:  2016-01-21       Impact factor: 4.294

9.  Women with Fragile X-associated Tremor/Ataxia Syndrome.

Authors:  Andrea Schneider; Scott Summers; Flora Tassone; Andreea Seritan; David Hessl; Paul Hagerman; Randi Hagerman
Journal:  Mov Disord Clin Pract       Date:  2020-09-23

10.  Increased severity of fragile X spectrum disorders in the agricultural community of Ricaurte, Colombia.

Authors:  Wilmar Saldarriaga; María J Salcedo-Arellano; Tatiana Rodriguez-Guerrero; Marcela Ríos; Andrés Fandiño-Losada; Julian Ramirez-Cheyne; Pamela J Lein; Flora Tassone; Randi J Hagerman
Journal:  Int J Dev Neurosci       Date:  2018-10-29       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.